Home > Oncology > ESMO 2021 > Breast Cancer > ESMO 2021 Highlights Podcast

ESMO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
ESMO 2021
DESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010

In this episode, Medicom’s correspondent covers 6 presentations from the European Society of Medical Oncology (ESMO 2021), held virtually from 16-21 September 2021. Medicom also interviews the presenter of the DESTINY-Breast03 trial, Prof. Javier Cortés, from Barcelona, Spain, included also in this podcast.

The topics discussed are:

  1. Longest breast cancer overall survival reported from frontline CDK4/6 inhibitor
CDK4/6 inhibitor ribociclib added to endocrine therapy extends overall survival (OS) in treatment-naïve postmenopausal patients with HR-positive/HER2-negative, advanced, metastatic breast cancer. Data from the MONALEESA-2 trial presented at the ESMO Congress 2021 showed that after a median follow-up of >6.5 years, median OS was 12 months longer for first-line ribociclib plus letrozole versus placebo plus letrozole.

  1. Trastuzumab deruxtecan triples breast cancer progression-free survival
At a prespecified interim analysis of DESTINY-Breast03, comparing trastuzumab deruxtecan (T-DXd) head-to-head with trastuzumab emtansine (T-DM1), T-Dxd reduced the risk of disease progression or death by 72% compared with T-DM1. There is an exclusive interview with the presenter Prof. Javier Cortés at the end of this podcast.

  1. Adjuvant immunotherapy reduces risk of disease recurrence compared with placebo in patients with stage II melanoma
The first interim analysis of KEYNOTE-716 suggests adjuvant pembrolizumab to be superior to standard-of-care observation for adults and children with completely resected high-risk melanoma.

  1. Three-year overall survival follow-up from CASPIAN
The phase 3 CASPIAN trial demonstrated first-line treatment with durvalumab plus platinum–etoposide (EP) to improve overall survival (OS) versus EP alone in patients with extensive stage small-cell lung cancer (SCLC). Three-year median follow-up demonstrates sustained OS benefit.

  1. Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
Updated results from the CheckMate-649 study report continued improvement of overall survival (OS) with nivolumab plus chemotherapy versus chemotherapy alone in patients with advanced gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma (GC/GEJC/EAC). In contrast, there was no OS benefit with nivolumab plus ipilimumab versus chemotherapy.

  1. Adjuvant atezolizumab lowers relapse rate in resected NSCLC
An exploratory analysis from the Impower010 trial adds support to the use of post-chemotherapy adjuvant immunotherapy for selected early stage non-small cell lung cancer (NSCLC).


Enjoy listening!

Copyright ©2021 Medicom Medical Publishers

Posted on